
BioAI Health is a biotechnology company that leverages world-leading AI technology to revolutionize precision medicine. They focus on mapping the causal biology of diseases, developing digital biomarkers, and identifying novel drug targets to accelerate clinical R&D and drug development. Their proprietary PredictX Platform utilizes cutting-edge multimodal causal AI and in-silico phenotype projection to analyze various data types, including digital pathology, multiomics, and real-world evidence. BioAI Health's cross-disciplinary team comprises industry experts with extensive experience in AI, drug development, and biomarker programs, enabling them to build successful partnerships within the biopharma industry. They aim to provide innovative digital biomarker solutions that improve patient outcomes by matching them with the most effective therapies and expanding access to clinical studies through cost-efficient H&E-based screening.

BioAI Health is a biotechnology company that leverages world-leading AI technology to revolutionize precision medicine. They focus on mapping the causal biology of diseases, developing digital biomarkers, and identifying novel drug targets to accelerate clinical R&D and drug development. Their proprietary PredictX Platform utilizes cutting-edge multimodal causal AI and in-silico phenotype projection to analyze various data types, including digital pathology, multiomics, and real-world evidence. BioAI Health's cross-disciplinary team comprises industry experts with extensive experience in AI, drug development, and biomarker programs, enabling them to build successful partnerships within the biopharma industry. They aim to provide innovative digital biomarker solutions that improve patient outcomes by matching them with the most effective therapies and expanding access to clinical studies through cost-efficient H&E-based screening.
Founded: 2020
Headquarters: Goffstown / Manchester, New Hampshire, USA
Tech: PredictX multimodal causal AI platform
Focus: Digital biomarkers, causal biology mapping, oncology & precision medicine
Team size (reported): 14 employees
Funding: Seed rounds; total reported $3,500,000 (USD)
Reducing time and cost in clinical R&D by identifying digital biomarkers and causal disease biology to improve therapy selection and accelerate drug development.
2020
Biotechnology
Reported earlier seed round
Most recent seed round reported
“Biomedical Investments”